Chuanshen Zhili Powder Veterinary Grade API is a multi-component botanical extract supplied as a powder for subsequent pharmaceutical processing into tablets, injections, capsules, powders, granules, premixes, and solutions. The model code is manufacturer-specific and is normally assigned according to extraction ratio, particle-size fraction, and route of administration; no harmonized public model designation currently exists for this product. Published product-specific numerical limits are limited; therefore, the following technical description does not assign release limits except where a recognized general method or process threshold applies. Each lot should be used only with the manufacturer’s certificate of analysis and the relevant registration dossier.

How does the veterinary grade differ from crude botanical powder, feed-grade phytogenic additives, and synthetic veterinary APIs?

The difference is specification depth and quality-system control, not a single chemical marker. Crude botanical powder retains intact cell-wall debris and may show wider assay variation because the active fraction is not standardized. Feed-grade phytogenic additives may use the same source material but are commonly released on macroscopic appearance and extraction yield rather than a validated HPLC marker-compound assay; they may also lack the residual solvent, mycotoxin, and elemental impurity tests required for a pharmaceutical API. The veterinary grade is manufactured with batch traceability, a certificate of analysis, retained reference samples, and change-control documentation. Single-molecule synthetic APIs differ further: they have a defined molecular mass, a single chromatographic peak, and a narrow thermal degradation range, whereas this product needs fingerprint profiling to manage natural multi-component variation. Direct substitution of the veterinary grade with crude powder or feed-grade additive is not appropriate without repeating stability, dissolution, and bioavailability studies.

In tablet and capsule production, the API is first screened through a 600 µm stainless-steel sieve to remove agglomerates. Direct compression is acceptable only when the powder flow, characterized under USP <1174>, gives a compressibility index of not more than 25 and a Hausner ratio of not more than 1.35; otherwise, wet or dry granulation is required. Wet granulation is performed in a high-shear mixer granulator with purified water or a binder solution, followed by wet milling and fluid-bed drying. The inlet air temperature is set so that the product temperature remains below the marker compound degradation threshold in the manufacturer's thermal stability data. Dried granules are compressed on a rotary tablet press; tablet breaking force is tested by USP <1217>, disintegration by USP <701>, and dissolution by USP <711>. In hard gelatin or hydroxypropyl methylcellulose capsule production, the blend is filled with a tamping pin or dosator encapsulator. Magnesium stearate is held at the minimum effective concentration because hydrophobic lubricants can delay dissolution of multi-component botanical powders. Capsule content uniformity is evaluated by USP <905>.

For powders, granules, and oral solutions, the API is dispersed or dissolved under continuous mixing. Powder sachet lines are operated with volumetric or auger filling; fill volume is corrected for bulk density and tapped density measured under USP <616>. Because botanical extract powders can absorb moisture rapidly, open handling should be limited above 60% RH. Premix batches are prepared in ribbon or paddle mixers by layering the active powder into a carrier; mixing time and impeller speed are established by HPLC assay of stratified thief samples. When reconstituted as an oral solution, the powder is added to purified water under high-shear mixing, pH is adjusted only within the stability range in the manufacturer's dossier, the solution is clarified by filtration, and assay is confirmed before filling. For multi-dose oral solution packaging, preservative efficacy should be tested under USP <51>. Published data for this specific configuration is limited; each formulation should be subjected to forced-degradation and compatibility studies before scale-up.

Pharmacopoeial test controls and grade-specific specification matrix

Release testing combines identification, assay, impurity, and physical tests. The table lists control parameters, reference methods, applicable grades, and the process variable controlled.

The matrix is not exhaustive. Injectable grades add bacterial endotoxin and sub-visible particulate controls; oral premix grades may add mycotoxin screening if the botanical source is susceptible to fungal contamination under storage. The manufacturer's dossier remains the controlling document for quantitative acceptance limits because published data for this specific configuration is limited.

Particle-size control and residual solvent profiles define the process windows for premix and granule manufacturing

Grade selection for premix and granule manufacturing is governed by bulk density, D90 particle size, and residual solvent class. A coarse oral-solid grade with D90 controlled by laser diffraction under USP <429> is usually selected for dry powders and feed premixes because it reduces dusting and segregation. If the same coarse fraction is used in an oral solution, dissolution time increases and a high-shear mixer may be needed to disperse the particles. A microfine injectable grade, if supplied, is milled to reduce insoluble residue but may show higher hygroscopicity and static charge, which affects flow into capsule and sachet fillers. Residual solvents are determined by headspace gas chromatography under USP <467> or ChP 0861; class 2 solvents, if used in extraction, must fall below the manufacturer's assigned limits and are not assumed to be absent from botanical extracts. The drying endpoint after wet granulation is a combined function of residual solvent limit, moisture specification, and marker compound degradation threshold. Published data for this specific configuration is limited; the acceptable endpoint should be confirmed by gas chromatography and stability-indicating HPLC at pilot scale.

Batch-to-batch variance in the milled extract is controlled by the extraction ratio and marker-compound assay, but compressibility, dissolution, and mix uniformity can shift if the particle-size distribution changes. The extract may contain hygroscopic carbohydrate fractions; after fine milling these fractions can plasticize under compaction and raise tablet hardness at constant compression force while slowing disintegration because water penetration into the tablet matrix is reduced. On a rotary tablet press, compression force and ejection force are monitored continuously; an upward ejection force trend at constant fill weight can indicate poor lubrication from an over-milled or moisture-affected fraction. In premix production, segregation is minimized by matching the active particle size to the carrier. Thief-probe sampling should include at least 10 evenly distributed points and be assayed by HPLC; acceptance is established from the required dose uniformity, not from API mass alone. If the mix shows high relative standard deviation, the ribbon mixer load should be checked against the manufacturer's minimum and maximum fill levels, and mixing time adjusted by replicate sampling rather than by a default time. Published data for this specific configuration is limited; process validation batches should include deliberate challenges at low and high mixer load and at upper moisture limits.

When the API is selected for injectable solutions, depyrogenation and sub-visible particle control are mandatory

Injectable solutions require a grade that is not only fine-particle-sized but also controlled for bacterial endotoxins by USP <85>, sterility by USP <71>, and particulate matter by USP <788>. The API powder is dissolved or dispersed in water for injection, then filtered through a prefilter and a 0.22 µm sterilizing-grade membrane. Sterile filtration of a botanical extract can be difficult if polysaccharides, proteins, or insoluble cell-wall fragments are present; membrane fouling and filter compatibility should be tested with the specific lot. Terminal steam sterilization may not be suitable if the marker compounds degrade above 100°C; in that case aseptic processing is used, with the powder handled in an ISO 7 or better controlled area according to ISO 14644-1 and filled in an ISO 5 unidirectional airflow zone. Endotoxin limits are route- and dose-specific; they cannot be derived from API mass alone. The depyrogenation of processing equipment by dry heat is performed before batch manufacture, but the API itself is not routinely depyrogenated by dry heat because thermal exposure may alter the chromatographic fingerprint. Injectable grades also require sub-visible particle counts under USP <788> after final filtration and before filling. Published data for this specific configuration is limited; thermal stability, filter compatibility, and endotoxin recovery should be qualified for each batch under the intended route.

Compared with fully synthetic small-molecule injectables, the botanical extract may require more filter area per batch because polysaccharides and colloidal material can reduce cumulative filter throughput. The formulation may also require pH stabilizers or antioxidants if the marker compounds are susceptible to oxidation after reconstitution. Oxidation boundaries should be established by forced-degradation studies under oxygen sparging and light exposure according to the relevant stability guideline.

Cleaning validation for multi-component botanical extracts uses a marker compound or total organic carbon as residue indicator after the cleaning procedure. If the same equipment is used for synthetic veterinary APIs, the extraction solubility of the powder in the cleaning matrix must be determined; hot alkaline detergent followed by purified water rinse is common, but the exact sequence depends on the extract's solubility and the surface material. Stainless steel contact surfaces are preferred, and gaskets should be inspected for extract residue adsorption. Cross-contamination limits are based on health-based exposure limits for the marker compound or the whole extract; a default 10 ppm residue limit is not automatically valid for a multi-component botanical API. Published data for this specific configuration is limited; residue limits and analytical methods should be established in the site cleaning validation master plan.

Storage conditions are assigned by the manufacturer's stability monograph. The powder is typically packaged in polyethylene/aluminum laminated bags inside a fiber drum, with desiccant when the moisture specification is low. Uncontrolled open handling above 60% RH can cause agglomeration, reduce flow, and change fill weight on volumetric powder lines. If the product is repackaged, the repackaging area should be humidity-controlled and the lot temperature monitored. The manufacturer's label should be consulted for shelf-life and any specific storage temperature range; this document does not assign a default expiry period because published data for this specific configuration is limited.